<div id="readability-page-1"><p><span>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)</span> was upgraded by analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report issued on Sunday.</p><p>Several other brokerages have also recently issued reports on ZNTL. Wedbush  reaffirmed a &#34;neutral&#34; rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. Wells Fargo &amp; Company dropped their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an &#34;equal weight&#34; rating for the company in a report on Thursday, August 7th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Thursday, August 7th. Finally, Leerink Partners  reissued a &#34;market perform&#34; rating and set a $2.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday. One analyst  has rated the stock with a Strong Buy rating, five have issued  a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $4.53.</p><p><b>View Our Latest Stock Report on Zentalis Pharmaceuticals</b></p><h2>Zentalis Pharmaceuticals Price Performance</h2><p>Shares of NASDAQ ZNTL opened at $1.33 on Friday. The company has a market cap of $96.09 million, a price-to-earnings ratio of -0.64 and a beta of 1.87. The stock's 50-day moving average is $1.52 and its two-hundred day moving average is $1.45. Zentalis Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $4.00. </p><p>Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.12.  Equities research analysts anticipate that  Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Zentalis Pharmaceuticals</h2><p>Hedge funds have recently modified their holdings of the company. Catalyst Funds Management Pty Ltd bought a new stake in shares of  Zentalis Pharmaceuticals in the 2nd quarter worth approximately $31,000.  Cerity Partners LLC raised its position in  Zentalis Pharmaceuticals by 58.7% in the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock worth $33,000 after purchasing an additional 7,579 shares during the last quarter.  Qube Research &amp; Technologies Ltd acquired a new position in  Zentalis Pharmaceuticals during the 2nd quarter valued at about $37,000.  Y Intercept Hong Kong Ltd bought a new position in  Zentalis Pharmaceuticals during the second quarter worth about $38,000.  Finally, Corient Private Wealth LLC bought a new position in  Zentalis Pharmaceuticals during the second quarter worth about $41,000. </p><h2>About Zentalis Pharmaceuticals</h2> (Get Free Report)<p>Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Zentalis Pharmaceuticals</li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li><li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li><li>3 Under-the-Radar AI Stocks to Buy on the Dip</li><li>Top Biotech Stocks: Exploring Innovation Opportunities</li><li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Wk5UTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zentalis Pharmaceuticals Right Now?</h2><p>Before you consider Zentalis Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.</p><p>While Zentalis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ZNTL

<p>Wall Street Zen upgraded Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a "sell" to "hold" rating. Other analysts have mixed ratings, with one "strong buy," five "hold," and one "sell." The stock has a consensus "hold" rating and an average price target of $4.53. Zentalis focuses on developing cancer therapeutics and has several ongoing clinical trials. Hedge funds have recently adjusted their holdings in the company.</p>

Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold